Seminars in Nephrology
Volume 31, Issue 6 , Pages 483-494 , November 2011

Update in Diuretic Therapy: Clinical Pharmacology

  • D. Craig Brater, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to D. Craig Brater, Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine Fairbanks Hall, 340 West 10th St, Suite 6200, Indianapolis, IN 46202

References 

  1. Chennavasin P, Seiwell R, Brater DC, Liang WMM. Pharmacodynamic analysis of the furosemide-probenecid interaction in man. Kidney Int. 1979;6:187–195
  2. Odlind B, Beerman B. Renal tubular secretion and effects of furosemide. Clin Pharmacol Ther. 1980;27:784–790
  3. Besseghir K, Rennick B. Renal tubule transport and electrolyte effects of amiloride in the chicken. J Pharmacol Exp Ther. 1981;219:435–441
  4. Kau ST. Handling of triamterene by the isolated perfused rat kidney. J Pharmacol Exp Ther. 1978;206:701–709
  5. Brater DC. Diuretic pharmacokinetics and pharmacodynamics. In:  van Boxtel CJ,  Holford NHG,  Danhof M editor. The in vivo study of drug action (Principles and applications of kinetic-dynamic modelling). Amsterdam: Elsevier Science Publishers; 1992;p. 253–275
  6. Fuller R, Hoppel C, Ingalls ST. Furosemide kinetics in patients with hepatic cirrhosis with ascites. Clin Pharmacol Ther. 1981;30:461–467
  7. Keller E, Hoppe-Seyler G, Mumm R, Schollmeyer P. Influence of hepatic cirrhosis and end-stage renal disease on pharmacokinetics and pharmacodynamics of furosemide. Eur J Clin Pharmacol. 1981;20:27–33
  8. Davies DL, Lant AF, Millard NR, Smith AJ, Ward JW, Wilson GM. Renal action, therapeutic use, and pharmacokinetics of the diuretic bumetanide. Clin Pharmacol Ther. 1974;15:141–155
  9. Holazo AA, Colburn WA, Gustafson JH, Young RL, Parsonnet M. Pharmacokinetics of bumetanide following intravenous, intramuscular, and oral administrations to normal subjects. J Pharm Sci. 1984;73:1108–1113
  10. Schwartz S, Brater DC, Pound D, Greene PK, Kramer WG, Rudy D. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide in patients with cirrhosis. Clin Pharmacol Ther. 1993;54:90–97
  11. Knauf H, Möhrke W, Mutschler E. Delayed elimination of triamterene and its active metabolite in chronic renal failure. Eur J Clin Pharmacol. 1983;24:453–456
  12. Villeneuve JP, Rocheleau F, Raymond G. Triamterene kinetics and dynamics in cirrhosis. Clin Pharmacol Ther. 1984;35:831–837
  13. Spahn H, Reuter K, Mutschler E, Gerok W, Knauf H. Pharmacokinetics of amiloride in renal and hepatic disease. Eur J Clin Pharmacol. 1987;33:493–498
  14. Murray MD, Haag KM, Black PK, Hall SD, Brater DC. Variable furosemide absorption and poor predictability of response in elderly patients. Pharmacotherapy. 1997;17:98–106
  15. Gehr TWB, Rudy DW, Matzke GR, Kramer WG, Sica DA, Brater DC. The pharmacokinetics of intravenous and oral torsemide in patients with chronic renal insufficiency. Clin Pharmacol Ther. 1994;56:31–38
  16. Vargo G, Kramer WG, Black PK, Smith WB, Serpas T, Brater DC. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin Pharmacol Ther. 1995;57:601–609
  17. Murray MD, Deer MM, Ferguson JA, Dexter PR, Bennett SJ, Perkins SM, et al. Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med. 2001;111:513–520
  18. Stroupe KT, Forthofer MM, Brater DC, Murray MD. Healthcare costs of patients with heart failure treated with torasemide or furosemide. Pharmacoeconomics. 2000;17:429–440
  19. Chaturvedi PR, O'Donnell JP, Nicholas JM, Shoenthal DR, Waters DH, Gwilt PR. Steady state absorption kinetics and pharmacodynamics of furosemide in congestive heart failure. Int J Clin Pharmacol Ther Toxicol. 1987;25:123–128
  20. Van Meyel JJM, Gerlag PGG, Smits P, Russel FG, Tan Y, Van Ginneken CA, et al. Absorption of high dose furosemide (frusemide) in congestive heart failure. Clin Pharmacokinet. 1992;22:308–318
  21. Bailie GR, Grennan A, Waldek S. Bioavailability of bumetanide in grossly oedematous patients. Clin Pharmacokinet. 1987;12:440–443
  22. Brater DC, Day B, Burdette A, Anderson S. Bumetanide and furosemide in heart failure. Kidney Int. 1984;26:183–189
  23. Vasko MR, Cartwright DB, Knochel JP, Nixon JB, Brater DC. Furosemide absorption altered in decompensated congestive heart failure. Ann Intern Med. 1985;102:314–318
  24. Wilcox CS, Mitch WE, Kelly RA, Skorecki K, Meyer TW, Friedman PA, et al. Response of the kidney to furosemide (I. Effects of salt intake and renal compensation). J Lab Clin Med. 1983;102:450–458
  25. Ferguson JA, Sundblad KJ, Becker PK, Gorski JC, Rudy DW, Brater DC. Role of duration of diuretic effect in preventing sodium retention. Clin Pharmacol Ther. 1997;62:203–208
  26. Hammarlund MM, Odlind B, Paalzow LK. Acute tolerance to furosemide diuresis in humans (Pharmacokinetic-pharmacodynamic modeling). J Pharmacol Exp Ther. 1985;233:447–453
  27. Wakelkamp M, Alván G, Gabrielsson J, Paintaud G. Pharmacodynamic modeling of furosemide tolerance after multiple intravenous administration. Clin Pharmacol Ther. 1996;60:75–88
  28. Almeshari K, Ahlstrom NG, Capraro FE, Wilcox CS. A volume-independent component to postdiuretic sodium retention in humans. J Am Soc Nephrol. 1993;3:1878–1883
  29. Kelly RA, Wilcox CS, Mitch WE, Meyer TW, Souney PF, Rayment CM, et al. Response of the kidney to furosemide (II. Effect of captopril on sodium balance). Kidney Int. 1983;24:233–239
  30. Wilcox CS, Guzman NJ, Mitch WE, Kelly RA, Maroni BJ, Souney PF, et al. Na+, K+, and BP homeostasis in man during furosemide: effects of prazosin and captopril. Kidney Int. 1987;31:135–141
  31. Petersen JS, Shalmi M, Abildgaard U, Christensen NJ, Christensen S. Renal effects of α-adrenoceptor blockade during furosemide diuresis in conscious rats. Pharmacol Toxicol. 1992;70:3–12
  32. Kaissling B, Stanton BA. Adaptation of distal tubule and collecting duct to increased sodium delivery (I. Ultrastructure). Am J Physiol. 1988;255:F1256–F1268
  33. Stanton BA, Kaissling B. Adaptation of distal tubule and collecting duct to increased Na delivery (II. Na+ and K+ transport). Am J Physiol. 1988;255:F1269–F1275
  34. Ellison DH, Velázquez H, Wright FS. Adaptation of the distal convoluted tubule of the rat. J Clin Invest. 1989;83:113–126
  35. Loon NR, Wilcox CS, Unwin RJ. Mechanism of impaired natriuretic response to furosemide during prolonged therapy. Kidney Int. 1989;36:682–689
  36. Kobayashi S, Clemmons DR, Nogami H, Roy AK, Venkatachalam MA. Tubular hypertrophy due to work load induced by furosemide is associated with increases of IGF-1 and IGFBP-1. Kidney Int. 1995;47:818–828
  37. Jentzer JC, DeWald TA, Hernandez AF. Combination of loop diuretics with thiazide-type diuretics in heart failure. J Am Coll Cardiol. 2010;56:1527–1534
  38. Voelker JR, Cartwright-Brown D, Anderson S, Leinfelder J, Sica DA, Kokko JP, et al. Comparison of loop diuretics in patients with chronic renal insufficiency: mechanism of difference in response. Kidney Int. 1987;32:572–578
  39. van Olden R, van Meyel JJM, Gerlag PGG. Sensitivity of residual nephrons to high dose furosemide described by diuretic efficiency. Eur J Clin Pharmacol. 1995;47:483–488
  40. Rudy DW, Gehr TWB, Matzke GR, Kramer WG, Sica DA, Brater DC. The pharmacodynamics of intravenous and oral torsemide in patients with chronic renal insufficiency. Clin Pharmacol Ther. 1994;56:39–47
  41. Wollam GL, Tarazi RC, Bravo EL, Dustan HP. Diuretic potency of combined hydrochlorothiazide and furosemide therapy in patients with azotemia. Am J Med. 1982;72:929–938
  42. Fliser D, Schröter M, Neubeck M, Ritz E. Coadministration of thiazides increases the efficacy of loop diuretics even in patients with advanced renal failure. Kidney Int. 1994;46:482–488
  43. Knauf H, Mutschler E. Diuretic effectiveness of hydrochlorothiazide and furosemide alone and in combination in chronic renal failure. J Cardiovasc Pharmacol. 1995;26:394–400
  44. Rudy DW, Voelker JR, Greene PK, Esparza FA, Brater DC. Loop diuretics for chronic renal insufficiency: a continuous infusion is more efficacious than bolus therapy. Ann Intern Med. 1991;115:360–366
  45. Kramer WG, Smith WB, Ferguson J, Serpas T, Grant AG, Black PK, et al. Pharmacokinetics of torsemide administered as an intravenous injection and as a continuous infusion to patients with congestive heart failure. J Clin Pharmacol. 1996;36:265–270
  46. Dormans TPJ, van Meyel JJM, Gerlag PGG, Russel FGM, Smits P. Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion. J Am Coll Cardiol. 1996;28:376–382
  47. Van Meyel JMM, Smits P, Dormans T, Gerlag PGG, Russel FGM, Gribnau FWJ. Continuous infusion of furosemide in the treatment of patients with congestive heart failure and diuretic resistance. J Intern Med. 1994;235:329–334
  48. Lahav M, Regev A, Ra'anani P, Theodor E. Intermittent administration of furosemide vs continuous infusion preceded by a loading dose for congestive heart failure. Chest. 1992;102:725–731
  49. Inoue M, Okajima K, Itoh K, et al. Mechanism of furosemide resistance in analbuminemic rats and hypoalbuminemic patients. Kidney Int. 1987;32:198–203
  50. Rane A, Villeneuve JP, Stone WJ, Nies AS, Wilkinson GR, Branch RA. Plasma binding and disposition of furosemide in the nephrotic syndrome and in uremia. Clin Pharmacol Ther. 1978;24:199–207
  51. Keller E, Hoppe-Seyler G, Schollmeyer P. Disposition and diuretic effect of furosemide in the nephrotic syndrome. Clin Pharmacol Ther. 1982;32:442–449
  52. Verbeeck RK, Patwardhan RV, Villeneuve JP, Wilkinson GR, Branch RA. Furosemide disposition in cirrhosis. Clin Pharmacol Ther. 1982;31:719–725
  53. Villeneuve JP, Verbeeck RK, Wilkinson GR, Branch RA. Furosemide kinetics and dynamics in patients with cirrhosis. Clin Pharmacol Ther. 1986;40:14–20
  54. Chalasani N, Gorski JC, Horlander JC, Craven R, Hoen H, Maya J, et al. Effects of albumin/furosemide mixtures on responses to furosemide in hypoalbuminemic patients. J Am Soc Nephrol. 2001;12:1010–1016
  55. Green TP, Mirkin BL. Resistance of proteinuric rats to furosemide: urinary drug protein binding as a determinant of drug effect. Life Sci. 1980;26:623–630
  56. Green TP, Mirkin BL. Furosemide disposition in normal and proteinuric rats: urinary drug-protein binding as a determinant of drug excretion. J Pharmacol Exp Ther. 1981;218:122–127
  57. Kirchner KA, Voelker JR, Brater DC. Intratubular albumin blunts the response to furosemide—a mechanism for diuretic resistance in the nephrotic syndrome. J Pharmacol Exp Ther. 1990;252:1097–1101
  58. Kirchner KA, Voelker JR, Brater DC. Binding inhibitors restore furosemide potency in tubule fluid containing albumin. Kidney Int. 1991;40:418–424
  59. Agarwal R, Gorski JC, Sundblad K, Brater DC. Urinary protein binding does not affect response to furosemide in patients with nephrotic syndrome. J Am Soc Nephrol. 2000;11:1100–1105
  60. Kirchner KA, Voelker JR, Brater DC. Tubular resistance to furosemide contributes to the attenuated diuretic response in nephrotic rats. J Am Soc Nephrol. 1992;2:1201–1207
  61. Nakahama H, Orita Y, Yamazaki M, et al. Pharmacokinetic and pharmacodynamic interactions between furosemide and hydrochlorothiazide in nephrotic patients. Nephron. 1988;49:223–227
  62. Ochs HR, Greenblatt DJ, Bodem G, Smith TW. Spironolactone. Am Heart J. 1978;96:389–400
  63. Shear L, Ching S, Gabuzda GJ. Compartmentalization of ascites and edema in patients with hepatic cirrhosis. N Engl J Med. 1970;282:1391–1396
  64. Overdiek HWPM, Hermens WAJJ, Merkus FWHM. New insights into the pharmacokinetics of spironolactone. 1985;38:469–474
  65. Greither A, Goldman S, Edelen JS, Benet LZ, Cohn K. Pharmacokinetics of furosemide in patients with congestive heart failure. Pharmacology. 1979;19:121–131
  66. Andreasen F, Mikkelsen E. Distribution, elimination and effect of furosemide in normal subjects and in patients with heart failure. Eur J Clin Pharmacol. 1977;12:15–22
  67. Brater DC, Chennavasin P, Seiwell R. Furosemide in patients with heart failure (Shift of the dose-response relationship). Clin Pharmacol Ther. 1980;28:182–186
  68. Alexander WD, Levine DF, Branch RA, Hartog M. The urinary sodium: potassium ratio and response to diuretics in resistant oedema. Postgrad Med J. 1977;53:117–121
  69. Van Vliet AA, Donker AJM, Nauta JJP, Verheugt FWA. Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor. Am J Cardiol. 1993;71:21A–28A
  70. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–1321
  71. Maren TH. Carbonic anhydrase inhibition (IX. Augmentation of the renal effect of meralluride by acetazolamide). J Pharmacol Exp Ther. 1958;123:311–315
  72. Rodicio JL, Hernando L. Effects and interactions of furosemide and acetazolamide on tubular function in rat kidney. Rev Esp Fisiol. 1977;33:113–118
  73. Gibson DG, Marshall JC, Lockey E. Assessment of proximal tubular sodium reabsorption during water diuresis in patients with heart disease. Br Heart J. 1970;32:399–405
  74. Earley LE, Martino JA. Influence of sodium balance on the ability of diuretics to inhibit tubular reabsorption (A study of factors that influence renal tubular sodium reabsorption in man). Circulation. 1970;42:323–334
  75. Brater DC, Kaojarern S, Chennavasin P. Pharmacodynamics of the diuretic effects of aminophylline and acetazolamide alone and combined with furosemide in normal subjects. J Pharmacol Exp Ther. 1983;227:92–98
  76. Nechay BR. Aminophylline and its relationship to some other diuretic agents in dogs. J Pharmacol Exp Ther. 1961;132:339–344
  77. Sigurd B, Olesen KH. The supra-additive natriuretic effect addition of theophylline ethylenediamine and bumetanide in congestive heart failure. Am Heart J. 1977;94:168–174
  78. Vargo DL, Brater DC, Rudy DW, Swan SK. Dopamine does not enhance furosemide-induced natriuresis in patients with congestive heart failure. J Am Soc Nephrol. 1996;7:1032–1037
  79. Denton MD, Chertow GM, Brady HR. Renal-dose dopamine for the treatment of acute renal failure: scientific rationale, experimental studies and clinical trials. Kidney Int. 1996;49:4–14
  80. Chertow GM, Sayegh MH, Allgren RL, Lazarus JM. Is the administration of dopamine associated with adverse or favorable outcomes in acute renal failure?. Am J Med. 1996;101:49–53
  81. Gottlieb SS. Renal effects of adenosine A1-receptor antagonists in congestive heart failure. Drugs. 2001;61:1387–1393
  82. Mitrovic V, Seferovic P, Dodic S, Krotin M, Neskovic A, Dickstein K, et al. Cardio-renal effects of the A1 adenosine receptor antagonist SLV320 in patients with heart failure. Circ Heart Fail. 2009;2:523–531
  83. Greenberg B, Thomas I, Banish D, Goldman S, Havranek E, Massie BM, et al. Effects of multiple oral doses of an A1 adenosine antagonist, BG9928, in patients with heart failure. J Am Coll Cardiol. 2007;50:600–606
  84. Cotter G, Dittrich HC, Weatherley BD, Bloomfield DM, O'Connor CM, Metra M, et al. The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. J Cardiac Fail. 2008;14:631–640
  85. Givertz MM, Massie BM, Fields TK, Pearson LL, Dittrich HC. The effects of KW-3902, an adenosine A1 receptor antagonist, on dieresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance. J Am Coll Cardiol. 2007;50:1551–1560
  86. Dittrich HC, Gupta DK, Hack TC, Dowling T, Callahan J, Thomson S. The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment. J Cardiac Fail. 2007;13:609–617
  87. Gottlieb SS, Brater DC, Thomas I, Havranek E, Bourge R, Goldman S, et al. BG971 (CVT-124), an adenosine A1 receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation. 2002;105:1348–1353
  88. Massie BM, O'Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, et al. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med. 2010;363:1419–1428

 Supported by the General Clinical Research Center (MO1 RR00750) and R01 DK 37994 and R01 AG 07631.

PII: S0270-9295(11)00132-X

doi: 10.1016/j.semnephrol.2011.09.003

Seminars in Nephrology
Volume 31, Issue 6 , Pages 483-494 , November 2011

Article Tools

* Image Usage & Resolution